idecabtagene vicleucel
idecabtagene vicleucel: 3 clinical trials tracked.
idecabtagene vicleucel evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about idecabtagene vicleucel, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (3)
Long-Term Safety Follow-Up Surveillance for Phase 3 Trial (KarMMA-9/CA089-1043) to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Primary endpoint: Participant adverse events
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Primary endpoint: Progression Free Survival (PFS)
Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation
Primary endpoint: feasibility of manufacturing Ide-Cel (to dose of at least 300 million cells)